Go Deep
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,512 | -2.0 | 0.74 | 0.03 | 417.12 |
| Oct 2026 | 23,563 | -1.9 | 0.69 | 0.03 | 388.34 |
| Oct 2026 | 23,565 | -2.0 | 0.69 | 0.03 | 387.44 |
| Oct 2026 | 23,599 | -1.8 | 0.66 | 0.03 | 368.44 |
| Oct 2026 | 23,578 | -1.9 | 0.68 | 0.03 | 380.21 |
| Oct 2026 | 23,553 | -1.9 | 0.70 | 0.03 | 393.49 |
| Oct 2026 | 23,602 | -1.8 | 0.66 | 0.03 | 366.03 |
| Oct 2026 | 23,615 | -1.8 | 0.65 | 0.03 | 358.69 |
| Oct 2026 | 23,650 | -1.7 | 0.61 | 0.03 | 341.22 |
Sionna Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -29,886,000.0 | -26,779,000.0 | -20,440,000.0 | -20,278,000.0 |
| EPS | -0.7 | -0.6 | -0.5 | -0.5 |
Sionna Therapeutics, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -75,268,000.0 | -61,688,000.0 | -47,263,000.0 | -40,240,000.0 |
| EPS | -1.9 | -1.5 | -1.7 | -2.3 |
Sionna Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 325,953,000.0 | 185,752,000.0 | 51,945,000.0 | 87,369,000.0 |
| Total Liabilities | 19,120,000.0 | 349,465,000.0 | 166,826,000.0 | 157,293,000.0 |
| Total Equity | 306,833,000.0 | -163,713,000.0 | -114,881,000.0 | -69,924,000.0 |
Owes vs Owns
Sionna Therapeutics, Inc. owed $0.06 for every $1 it owned in Jun 2026, down from $1.80 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.06× | 0.06× | 1.88× | 3.21× | 1.80× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sionna Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 72.4%Fixed assets (tangible) 2.8%Long-term investments 22.8%Other assets 2.0%
How it's funded — Dec 2025
Long-term debt 2.3%Other liabilities 3.0%Shareholders' equity 94.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 235.9 | 147.5 | 38.5 | 82.6 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 9.2 | 10.3 | 11.7 | 2.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 74.4 | 20.5 | 0.0 | 0.0 |
| Other assets | 6.5 | 7.4 | 1.7 | 2.2 |
| Liabilities & equity | ||||
| Short-term debt | 1.3 | 1.1 | 0.7 | 0.0 |
| Long-term debt | 7.4 | 8.7 | 9.7 | 0.0 |
| Payables | 0.8 | 1.2 | 0.7 | 0.6 |
| Other liabilities | 9.7 | 338.5 | 155.6 | 156.7 |
| Shareholders' equity | 306.8 | -163.7 | -114.9 | -69.9 |
| Net tangible assets | 306.8 | -163.7 | -114.9 | -69.9 |
Sionna Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -66,297,000.0 | -52,787,000.0 | -43,699,000.0 | -36,068,000.0 |
| Investing Activities | -118,749,000.0 | -126,913,000.0 | 27,352,000.0 | -29,263,000.0 |
| Financing Activities | 205,710,000.0 | 178,967,000.0 | 31,000.0 | 110,855,000.0 |